clinical trial · NCT05733624
Clinical Trial to Evaluate the Safety and Efficacy of SCAI-001 Compared to Restasis
SCAI Therapeutics·phase2·completed·n = 116
Dry Eye SyndromesSCAI-001 0.01% eyedropSCAI-001 0.02% eyedropRestasis 0.05% eyedrop
brief summary
This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.
started
Jan 5, 2023
primary completion
Aug 23, 2023
completion
Feb 2, 2024
last updated
Feb 5, 2024
official title
A Multicenter, Active Control, Parallel Group, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops in Patients With Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol